IBIO-600 Phase 1 enrollment completed; $88M cash runway reported

iBio says enrollment is complete in its Phase 1 single-ascending-dose trial of IBIO-600 and expects interim human data soon. An updated presentation shows $88.0M cash runway. HC Wainwright initiated coverage with a Buy rating and a $7.00 target.